CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino
Go back to CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino| (NASDAQ: CRSP) | Delayed: 54.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.36 | 52 Week High | $18.88 | |||
| Open | $54.36 | 52 Week Low | $13.75 | |||
| Day High | $54.36 | P/E | N/A | |||
| Day Low | $54.36 | EPS | $0.00 | |||
| Volume | 2,700 | |||||
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 466.79 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $466.79 | 52 Week High | $134.71 | |||
| Open | $466.79 | 52 Week Low | $73.31 | |||
| Day High | $466.79 | P/E | N/A | |||
| Day Low | $466.79 | EPS | $-1.98 | |||
| Volume | 1,558 | |||||
